[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644059":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":39,"centralContacts":44,"locations":34,"responsibleParty":49,"collaborators":34,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":34,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":34,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":74,"whyStopped":34,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":34},{"fullName":5,"class":6},"Arcus Biosciences, Inc.","INDUSTRY",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"SAD Part","EXPERIMENTAL","Escalating single oral doses of AB102 will be given to participants",[13],"Drug: AB102",{"label":15,"type":10,"description":16,"interventionNames":17},"SAD Part Placebo","Escalating single oral doses of placebo will be given to participants",[18],"Other: Placebo",{"label":20,"type":21,"description":22,"interventionNames":23},"MAD Part","PLACEBO_COMPARATOR","Escalating multiple oral doses of AB102 will be given to participants",[13],{"label":25,"type":21,"description":26,"interventionNames":27},"MAD Part Placebo","Escalating multiple oral doses of placebo will be given to participants",[18],[29,35],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","AB102","Administered orally as specified in the treatment arm",[20,9],null,{"type":36,"name":37,"description":32,"armGroupLabels":38,"otherNames":34},"OTHER","Placebo",[25,15],[40],{"name":41,"affiliation":42,"role":43},"Medical Director","Arcus Biosciences","STUDY_DIRECTOR",[45],{"name":41,"role":46,"phone":47,"phoneExt":34,"email":48},"CONTACT","+1-510-462-3330","ClinicalTrialInquiry@arcusbio.com",{"type":50,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100644059","phase-1-a-study-to-investigate-the-safety-tolerability-and-pk-of-ab102-in-healthy-participants-100644059",false,"NCT07662057","A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants","A Double-Blind, Randomized, Placebo-Controlled, Combined Single Ascending Dose and Multiple Ascending Dose First-In-Human Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AB102 in Healthy Participants","Inclusion Criteria:\n\n* Understands the study procedures in the Informed Consent Form and is willing and able to comply with the protocol.\n* BMI: 19.0 to 30.0 kg\u002Fm2, inclusive, at screening.\n* All prescribed medication must have been stopped at least 30 days prior to admission to the clinical site. An exception is made for hormonal contraceptives that may be used throughout the study.\n* Good physical and mental health based on medical history, physical examination, clinical laboratory, ECG, vital signs, and complete neurological examination, as judged by the Investigator.\n* Participants must follow protocol-specified contraception guidance.\n\nExclusion Criteria:\n\n* Have a history of relevant atopy, drug hypersensitivity and\u002For food allergies.\n* Using tobacco products within 3 months prior to the screening.\n* Have a significant infection or known inflammatory process on screening or admission.\n* Have received any vaccination within 14 days of admission date for non-live vaccines or 28 days of admission date for live attenuated vaccines.\n* History of alcohol abuse or drug addiction in the last 2 years (including soft drugs like cannabis products).\n\nNOTE: Other protocol defined Inclusion\u002FExclusion criteria may apply.",true,"ALL","18 Years","55 Years",{"count":63,"type":64},130,"ESTIMATED","INTERVENTIONAL",[67],"PHASE1","The purpose of this study is assess the safety and tolerability of AB102 and characterize the pharmacokinetics (PK) profile of AB102 after single and multiple ascending oral dose(s).",[70],"Healthy Volunteers",[31,72,73],"Healthy Volunteer","MRGPRX2 inhibitor","NOT_YET_RECRUITING","2026-06-22",{"date":77,"type":78},"2026-06-25","ACTUAL",{"date":80,"type":64},"2026-07",{"date":82,"type":64},"2026-12",{"name":5,"class":6}]